Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13939)	7/3/2000 5:34:54 PM
From: Cacaito	Respond to of 17367

Blueg, you just completed the transition, the subject is xoma, not my personal emotions!. Anyway, pampering xoma is now the goal of the non idiotic side of the board! Do you think that repeating ad nauseaum your baboon abstract misconception is respect for any intelligence, even the baboons? xoma has two clear human studies with bpi, trauma II 400 patients, trauma III 1000 patients, both FAILURE, and you keep repeating a BABOON study!!! talking insults to intelligence. More over, the phase III meningo/bpi study, 400 human subjects, is further prove of failure, not my intelligence view, not this board, not the baboons, BUT the FDA!!! The above got nothing to do with my emotions, is pure real objective information!

To: Bluegreen who wrote (13939)	7/3/2000 5:58:27 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

And Blue, yes, lets take bpi out of the value (I have mentioned that 20 times), and maybe one will have a more fair share price to pay for it, cause there is LOTS of RISKs (proven failures all over the place) in the bpi line. No value in the rest of the technology for many years or decades if at all. And the only value is anticdlla and Yes there is heavy competition in the psoriasis AND the transplant field (anticd11a will be a late latecomer). Baxter is not to be trusted, they were supposed to be the nice link to the FDA, results? REJECTION!